Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Radicava edaravone Amyotrophic lateral sclerosis Reimburse with clinical criteria and/or conditions Complete
Ralivia Tramadol hydrochloride Pain Do not list Complete
RAPAFLO Silodosin Benign prostatic hyperplasia Do not list Complete
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque List with clinical criteria and/or conditions Complete
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque N/A Complete
Rasilez Aliskiren Hypertension Do not list Complete
Ravicti glycerol phenylbutyrate Urea cycle disorders Reimburse with clinical criteria and/or conditions Complete
Rebif Interferon beta-1a Clinically isolated syndrome Do not list Complete
Reblozyl luspatercept beta-thalassemia associated anemia Reimburse with clinical criteria and/or conditions Complete
Reblozyl luspatercept Myelodysplastic syndromes-associated anemia Reimburse with clinical criteria and/or conditions Complete